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BACKGROUND: The incidence of ovarian cancer has been increasing worldwide and it is currently the leading cause of death from
gynaecological malignancy. Unlike breast cancer, the prognostic role of the human epidermal growth factor receptor-2 (HER-2) in
ovarian carcinoma remains controversial.
METHODS: The aim of this preclinical study was to further characterise the biological, molecular and cellular effects of trastuzumab
(Herceptin) using NIH-OVCAR-3 and derived cell lines both in vitro and in vivo.
RESULTS: In vitro assessments have shown that trastuzumab treatment inhibited total and phosphorylated HER-2. This was associated
with inhibition of the phosphorylated form of phosphatase and tensin homologue (PTEN), mitogen-activated protein kinase and AKT,
and the total level of p27
kip. Inhibition of PTEN is associated with phosphorylated MEK1/2 upregulation, suggesting a specific inhibition
of the protein phosphatase function of PTEN. Moreover, trastuzumab induced the upregulation of RhoB. These molecular
modifications promote inhibition of cell migration and potentially restoration of tumour cell contact inhibition. RhoB induction
in NIH-OVCAR-3 control cell lines mimics the molecular and cellular trastuzumab long-time exposition effects. RhoB inhibition in
NIH-OVCAR-3 long-time exposed to trastuzumab cell line reverses the cellular and molecular effects observed in this model. In vivo
examinations have shown that these changes are also associated with the restoration of structural, morphological and normal
functions of the peritoneum of an ovarian carcinoma mouse model.
CONCLUSION: These results provide an indication of the mechanisms underlying the anti-tumour activity of trastuzumab that strongly
implicate RhoB in an ovarian carcinoma model that does not show HER-2 amplification or overexpression. These findings highlight
that trastuzumab effects involve a possible cross-talk between RhoB and PTEN in the early stages of tumour re-growth in a model of
micrometastatic ovarian cancer.
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The incidence of ovarian cancer has been increasing in the recent
decades and it is currently the leading cause of death from
gynaecological malignancy (Ozols, 2002). Initially, ovarian cancer
is relatively asymptomatic and therefore 450% of patients have
advanced or metastatic disease associated with ascites and
peritoneal dissemination at the time of diagnosis (Ozols, 2002).
Although progress in the routine use of anti-cancer agents, such as
platinum analogues and paclitaxel, has improved therapeutic
response in advanced ovarian cancer, long-term prognosis remains
unsatisfactory (McGuire et al, 1996). Peritoneal dissemination of
disease is the most common form of progression and recurrence.
Both the size of disseminated tumours and the amount of ascitic
fluid are known to be inversely correlated with prognosis, and as in
any tumour, dissemination is crucial for prognosis (Ozols, 1997).
In retrospective immunohistochemistry analyses, 25% of
primary ovarian carcinomas express the human epidermal growth
factor receptor-2 (HER-2)-encoded receptor. However, unlike
breast cancer, it is controversial to what extent HER-2 ampli-
fication and protein overexpression correlate with prognosis
(Fan et al, 1994; Fajac et al, 1995), although it has been reported
that HER-2 expression is more frequent in ovarian carcinomas
relapsing after chemotherapy (Meden et al, 1998). The HER-2
(ERBB2/neu) proto-oncogene encodes for a 185-kDa cell-surface
glycoprotein, a transmembrane tyrosine kinase receptor protein
that belongs to the epidermal growth factor receptor (EGFR)
family (HER-1, HER-2, HER-3, HER-4) (Slamon et al, 1989;
Baselga and Albanell, 2001; Ross et al, 2003). The HER family
participates primarily in the transduction of proliferation signal
pathways from various ligands, and this process involves
dimer formation between different HER receptors. Trastuzumab
(Herceptin) is the first anti-HER-2 antibody to be used for the
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streatment of breast cancer expressing high levels of HER-2 (Press
et al, 2002; Ross et al, 2003) and in their adjuvant setting. In
metastatic breast cancer with HER-2 amplification, the addition of
trastuzumab to standard chemotherapy yields significantly higher
response rates and prolonged survival (Baselga et al, 1998; Pegram
and Slamon, 1999). In vitro and in vivo studies have suggested that
trastuzumab downregulates the HER-2 receptor and consequently
inhibits downstream pathways involved in cell proliferation,
survival (Klapper et al, 2000; Delord et al, 2005) and metastasis
(Klapper et al, 2000). In breast cancer, trastuzumab dramatically
enhances the chemosensitivity of tumour cells. However, the
mechanism of action of trastuzumab is still not fully understood,
more particularly, trastuzumab potential interactions with the
early stages of dissemination of the metastasic process in breast
and other cancers.
We have previously reported that trastuzumab as a single agent
can cure mice in a micrometastasis model of ovarian carcinoma
that do not overexpress HER-2 if started soon after induction
chemotherapy (Delord et al, 2005). In the same study, we showed
that the effects of trastuzumab in vivo are associated in vitro with
a slight inhibition of the proliferative mitogen-activated protein
kinase (MAPK) signal transduction pathway and a stronger
inhibition of AKT phosphorylation.
The aim of this study was to further characterise the biological,
molecular and cellular effects of trastuzumab in human ovarian
carcinoma cell models without HER-2 gene amplification or
protein overexpression.
MATERIALS AND METHODS
Animals and agents
Female Swiss athymic nude mice, 4–5-weeks-old (Charles River
Laboratories, L’Arbresele, France) were housed in filtre-capped
cages and kept in a sterile facility, which was maintained in
accordance with the standards of the Federation of European
Laboratory Animal Science Associations. The study was initiated
after 2 weeks quarantine. Trastuzumab (Herceptin, TZ) was
obtained from F. Hoffmann-La Roche Ltd (Basel, Switzerland).
Antibodies
The following antibodies were used: anti-Phospho-ErbB2/HER-2
(Tyr1248) provided by Upstate Ab (Euromedex, Mundolsheim,
France); anti-total HER-2 (c-erbB-2/HER-2/neu Ab-12, clone
CB11) and anti-tubulin-b were from NeoMarkers Ab (Interchim,
Montluc¸on, France); anti-active MAPK pAb, rabbit (pTEpY) was
from Promega (Charbonnie `res-les-bains, France); the phospho-
AKT antibody (CR 473 Lot-6) and the total AKT antibody
(Lot-6) were from Ozyme (Saint-Quentin-en-Yvelines, France);
the anti-ERK (c-16) and anti-RhoB rabbit were from Santa Cruz
Biotechnology (Tebu-Bio SA, Le Perray en Yvelines, France);
the anti-p27
Kip was from Dakocytomation (Trappes, France); the
anti-total and phosphorylated form of phosphatase and tensin
homologue (PTEN) were from Cell Signaling (Ozyme); the anti-
phospho-MEK1/2 (Ser218/Ser222) was from Zymed Laboratories
(Invitrogen, Cergy Pontoise, France) and the peroxidase-conju-
gated secondary mouse or rabbit antibodies were from Bio-Rad
(Marnes la Coquette, France).
OVCAR-3 animal model
The Claudius Regaud Institute animal ethics committee approval
was obtained for the use of the animal model and the study
protocols. The OVCAR-3 tumour model has been described
previously (Ortaldo et al, 1986; Guichard et al, 2001). Briefly,
a xenograft in nude mice was obtained after intraperitoneal (i.p.)
implantation of 4.5 10
7 cells of the NIH-OVCAR-3 tumour cell
line (American Type Culture Collection, ATCC-LGC Promochem
Sarl, Molsheim France, HTB-161) and maintained in vivo in the
laboratory. The i.p. xenograft was passaged as follows: the
peritoneal cavity of mice with ascites was irrigated with sodium
chloride solution (0.9%), and the wash was combined with ascites.
The cells were washed twice in phosphate-buffered saline (PBS).
The pellet was resuspended and diluted 1:3 in saline solution.
Each mouse received 1ml of this cell suspension i.p., which
represented 10–12 10
6 cells. Mice with i.p. tumour xenograft
were inspected daily for assessment of overall clinical conditions
and assessment of food and water intake. When the tumour
reached a macroscopic stage of ascites, mice were inspected twice
a day and killed before occurrence of poor health conditions.
Treatment and microscopic examination
The treated group of nude mice bearing OVCAR-3 macroscopic
ascites received 1ml of trastuzumab administered i.p. at a dose of
150mgml
 1 per day for 24, 48 and 72h. Naive nude mice were i.p.
injected once daily, for 3 days with 1ml of either RPMI-1640 or the
24-h serum-free cleared supernatant collected from OVCAR-3 cells
in culture. Mice were killed and the peritoneum removed, formalin
fixed and paraffin embedded. Thick sections of 5mm from each
block were stained with haemalum–eosin and constituted the
basis of microscopic examination and photographed.
Peritoneal permeability test
Peritoneal permeability was assessed using an innovative, simple
and convenient technique derived from the method described by
Das et al (2004). It consists of i.p. injection of 370MBq (10mCi)
99
m technetium radiolabel diethylene triamine penta-acetic acid
(99
mTc-DTPA) in nude mice bearing OVCAR-3 macroscopic
ascites (treated with or without trastuzumab as described above).
Peritoneal permeability was assessed according to the 99
mTc-
DTPA elimination from the peritoneal cavity evaluated from the
radioactivity distribution in the abdominal region of the mice vs its
bladder appearance. A dynamic acquisition of planar images
was performed using a gamma camera (GEHC – crystal thickness
of 5/800) equipped with low-energy high-resolution collimators.
The acquisition setup was as follows.
  Mice were anaesthetised by an i.p. injection of ketamin plus
xylazin solution at 100 and 5mgkg
 1, respectively.
  They were then placed in a prone position directly on the safety
cover of the detector and eight images of equal duration were
acquired for a total duration time of 32min (4min per frame).
  The matrix size was 256 256 with an acquisition zoom of
1.8 corresponding to a pixel size of 12276mm.
  Image analysis was performed on a Xeleris workstation (GEHC
BUC, Sur Yvette, France; version 2.728 GEHC – Waukesha).
The variation of radioactivity displayed by different organs (such
as the abdomen, left and right kidney, bladder) was recorded using
elliptical regions of interest (ROIs) surrounding each organs on a
summation image (obtained by addition of the eight images of the
data set). The ROIs were automatically duplicated on each frame of
the data set. Time–activity curves were then plotted for all ROIs
and corresponding data were extracted to an EXCEL spreadsheet.
Results are expressed as mean±s.e.m. of at least two independent
experiments with three mice per group.
Cell culture
NIH-OVCAR-3 (American Type Culture Collection, ATCC-LGC
Promochem Sarl; HTB-161) cells without HER-2 protein over-
expression or gene amplification (NIH-OVCAR-3 wild type:
OVCAR-3WT) were cultured routinely in RPMI-1640 containing
10% heat-decomplemented serum, supplemented with 20ngml
 1
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sepidermal growth factor (EGF) (Hoffmann-La Roche Ltd.,
Meylan, France), 10mgml
 1 insulin (Roche) and 2mML-glutamine
(Cambrex Biosciences, Emerainville, France) at 371C and 5% CO2.
However, oestradiol interferes with the effects of trastuzumab on
HER-2 signalling and phenol red acts as an oestradiol-like factor
(Treeck et al, 2003); therefore, before any in vitro study, OVCAR-3
cells were cultured for a week in an otherwise identical medium
lacking phenol red.
OVCAR-3-sublines development
NIH-OVCAR-3 ascites cells (OVCAR-3A) were generated from
the mice model of peritoneal ovarian carcinoma as follows. The
peritoneal cavity of mice with ascites was irrigated under sterile
conditions with sodium chloride solution (0.9%), and the wash was
combined with ascites. The cells were washed twice in PBS; the
pellet was resuspended in phenol red-free RPMI-1640 medium
(as described above) and cultured at 371C and 5% CO2. On the
basis of these cells and after 1-month culture, a new model was
prepared, NIH-OVCAR-3 ascites cells (OVCAR-3A). These cells
were then used to generate a third cell model long-term
trastuzumab-exposed cells (OVCAR-3LTE). Briefly, OVCAR-3A
cells were cultured in phenol red-free RPMI-1640 medium
containing 10% heat-decomplemented serum and treated three
times a week with trastuzumab 150mgml
 1 during 6 months.
RhoB upregulation, Adeno-RhoB: adenoviral constructs
and transduction protocol
Replication-defective (E1,E3) Ad vectors expressing RhoB under
the transcriptional control of the CMV promoter were constructed
using the AdEasy System (Qbiogen, F, Illkirch, France). Initially, a
BglII-BamH1 fragment containing RhoB and obtained from
digestion of the pGR5-2-RhoB plasmid already described was
subcloned into BamHI-digested pAdenoVATOR-CMV5(CuO)-ires
GFP transfer vector (Qbiogen, F) to obtain the shuttle vector
pAdRhoB. This vector allows transgene expression driven by the
cumate-inducible CMV5(CuO) promoter. An internal ribosome
entry-site sequence ensures co-expression of GFP. The replication-
defective vector AdpRhoB and the control empty vector AdeGFP
(encoding enhanced green fluorescent protein) were produced as
described previously (Malecaze et al, 2006). Viral titres were
determined by optical absorbance at 260nm (1OD¼1 1012
physical particle per ml). A total of 140 10
3 cells were plated on a
35-mm dish 24h before transduction. On day 0, cells were
transduced with viral vectors at an MOI of 10/1. Cells were then
amplified and used for experiments of western blot analysis of
RhoB, PTEN, MEK1-2 expression and/or activity, immunofluores-
cence assay for actin network organisation and density evaluation
and migration assay as described next in this study.
RhoB inhibition ShRNA RhoB: lentiviral vector
LVTHM is a lentiviral vector (LV) encoding the shRNA RhoB1
(50-CGCGTCCCCGGCATTCTCTAAAGCTATGTTCAAGAGACATA
GCTTTAGAGAATGCCTTTTTGGAAAT-30) or RhoB2 (50-CGCGT
CCCCTTGATATCCCTTGTCTGTAATTCAAGAGATTACAGACAA
GGGATATCAATTTTTGAAA-30) under the control of the H1
promoter. 293T cells were kindly provided by Genethon (Evry,
France). Generation of 293T-LVTHM-shB2 and preparation of
high-titre LV pseudotyped with the VSV-G protein have been
described previously. Viruses containing supernatants were
prepared as described elsewhere (Couderc et al, 2008). In all,
1 10
6 cells were plated on 100-mm dishes 24h before transduc-
tion with viral vectors at an MOI of 10:1. Cells were then used for
experiments of western blot analysis of RhoB, PTEN, MEK1-2
expression and/or activity, immunofluorescence assay for actin
network organisation and density evaluation and migration assay
as described next in this study.
Cell growth determination
OVCAR-3WT, OVCAR-3A or OVCAR-3LTE cells were seeded
in RPMI-1640 phenol red-free medium containing 10 or 2.5%
heat-decomplemented serum at 2000 and 4000 cells per well for
OVCAR-3WT and OVCAR-3A, respectively, and 2000 and 3000
cells per well for OVCAR-3LTE in a 96-well plate in sextuplet on
day 0. On day 1 and every day, cells were treated with either vehicle
or trastuzumab in a concentration range of 0–600mgml
 1. The
number of cells was evaluated on day 0 (18h after plating) and
every 24h as indicated by a sulforhodamine B test described
elsewhere (Skehan et al, 1990). Briefly, sulforhodamine B is a
colorimetric assay determining the protein sample content directly
correlated with the number of cells.
Phosphorylated quantification
OVCAR-3WT, OVCAR-3A or OVCAR-3LTE cells were plated at
1 10
6 cells per 100-mm culture dishes in RPMI-1640 phenol red-
free medium supplemented with 10% heat-decomplemented serum
and 2mML -glutamine in 100-mm culture dishes. Cells were serum
starved for 24h and then treated with either trastuzumab
(150mgml
 1) or vehicle for 24h. When indicated, EGF stimulation
(20ngml
 1) was performed during the last 15min of treatment.
Concentration of phosphorylated EGFR was measured using an
active EGFR enzyme immunoassay (EIA) Kit (Takara Biomedicals,
Tokyo, Japan) following the supplier’s instructions and expressed
as the amount of phosphorylated EGFR (fmolml
 1).
Fluorescence
Cells were seeded on glass coverslips into 6-well plates (Nunc Inc.,
Naperville, IL, USA) at a density of 8 10
4 or 1 10
5 cells per well
in RPMI-1640 phenol red-free medium supplemented with 10%
heat-decomplemented serum and 2mML -glutamine. After 48h
cells were serum starved or not for 48h. Cells were then fixed in
3% paraformaldehyde and permeabilised into 0.1% Triton X-100
in PBS. Actin fibres were detected by incubation with tetra-
methylrhodamine isothiocyanate-labelled phalloidin (Molecular
Probes, Invitrogen). Cells were viewed on a Zeiss Axiophot
microscope (Zeiss, Sartrouville, France), and photographed using
a Princeton camera (Princeton, Sartrouville, France).
Focus-formation assay
OVCAR-3WT, OVCAR-3A or OVCAR-3LTE cells were seeded at
1 10
6 cells in 60-mm culture dishes in RPMI-1640 phenol red-
free medium supplemented with 10% heat-decomplemented serum
and 2mML-glutamine. For OVCAR-3WT, OVCAR-3A studies were
also performed in RPMI-1640 containing 10% heat-decomplemen-
ted serum, supplemented with 20ngml
 1 EGF, 10mgml
 1 insulin
and 2mML -glutamine. Cell foci were scored 15 days after cell
confluence and photographed.
Plating efficiency determination
OVCAR-3WT, OVCAR-3A or OVCAR-3LTE cells were seeded at
300 cells per 60-mm culture dishes in RPMI-1640 phenol red-free
medium supplemented with 10% heat-decomplemented serum and
2m ML -glutamine. For OVCAR-3WT, OVCAR-3A experiments
were also performed in RPMI-1640 containing 10% heat-decom-
plemented serum, supplemented with 20ngml
 1 EGF, 10mgml
 1
insulin and 2mML -glutamine. Cell plating efficiency was scored
10 or 15 days later, respectively, by fixing with ethanol–formol–
acetic acid (75%/20%/5%) and staining with crystal violet.
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sAnchorage-independent growth assays
Cells were seeded at 1000 cells per well in 12-well plates in
duplicate in 0.3% agar over a 0.6% agar layer. Cells were fed twice
weekly until colonies grew to a suitable size for observation (B12
days). Colonies were photographed after 4h of incubation with
1mgml
 1 diphenyltetrazolium bromide in RPMI at 371C. The
growth of OVCAR-3WT and OVCAR-3A colonies was compared
with that of OVCAR-3LTE colonies.
Migration assay
Cells were plated at 1 10
6 per 60-mm culture dishes in RPMI-
1640 phenol red-free medium supplemented with 10% heat-
decomplemented serum and 2mML -glutamine for OVCAR-3LTE
and with 20ngml
 1 EGF and 10mgml
 1 insulin for OVCAR-3WT
and OVCAR-3A, respectively. When cells were confluent, ‘scratch’
wounds were created by scraping confluent cell monolayers with a
sterile pipette tip to make a gap. The scraped down cells were
washed by serum-free medium and re-fed with the appropriate
medium. Migration was scored and photographs taken on the
‘scratch’ wound day and every 12h.
Western blot analysis
On day 1, 1.5 10
6 OVCAR-3WT, OVCAR-3A or OVCAR-3LTE
cells were plated in phenol red-free RPMI-1640 medium containing
10% heat-decomplemented serum supplemented with 2mM
L-glutamine and 20ngml
 1 EGF, 10mgml
 1 insulin for OVCAR-
3WT, OVCAR-3A in 100-mm culture dishes. After 48h, cells were
serum starved and treated with either vehicle or trastuzumab
150mgml
 1 for 24–72h. Before the end of the experiment and
when necessary, cells were treated with 20ngml
 1 EGF for the last
15min of the experiment. The cells were harvested and lysed in
lysis buffer (Tris 50mM pH 8, NaCl 150mM, 0.1% NP40, 5mM
MgCl2,5 0m M NaF, 2mM PMSF, 10mM DTT, 2mM orthovanadate,
5mgml
 1 sodium dexoxycholate, 6.4mgml
 1 phosphatase sub-
strate; Sigma, Lyon, France; 104). For HER-2, HER-1, MAPK, AKT,
p27
Kip, PTEN, MEK, RhoB or b-tubulin analysis, 70mg of the
cleared lysates were separated on a 7.5 or 12.5% sodium dodecyl
sulphate polyacrylamide gel blotted to PVDF membranes
(Amersham Pharmacia Biotech, Orsay, France), and incubated
with specific antibodies. Detection was performed using perox-
idase-conjugated secondary antibodies (Bio-Rad) and an enhanced
chemiluminescence detection kit (Amersham Pharmacia Biotech).
Blots were scanned and analysed and quantified with Molecular
Dynamics (Saclay, France) densitometer and ImageQuant software
(GE Healthcare, Saclay, France).
Statistical analysis
All results are expressed as mean±s.e.m. Results were analysed
using Student’s t-tests, and a P-value o0.05 was accepted as
statistically significant.
RESULTS
In vivo
Pathological effects of trastuzumab The pathological pattern of
the peritoneum was evaluated 20 days after OVCAR-3WT implan-
tation driving to macroscopic peritoneal ascites (Figure 1A). We
compared the naive nude mice group injected with RPMI-1640
(Figure 1A3), which is the control group of Figure 1A, with the
untreated mice group (Figure 1A1) and trastuzumab-treated
animals (Figure 1A2). Mice were killed and the peritonea were
dissected to assess the pathological morphology of the peritoneum.
Compared with the control group (naive nude mice injected with
RPMI-1640: Figure 1A3), untreated mice displayed inflammatory
modifications of the peritoneum (Figure 1A1). These lesions
consisted of mesothelial hyperplasia on the surface of plump
and non-cohesive mesothelial cells and in the underlying layers
of vascular and fibroblastic granulation tissue. Tumour cell
clusters infiltrating the peritoneum were focally seen. By contrast,
trastuzumab treatment dramatically decreased the number
and size of tumour cell clusters infiltrating the peritoneum
(Figure 1A2). It also induced restoration of a normal peritoneal
structure with a continuous surface layer of flattened cells similar
to the light microscopic characteristics of the normal peritoneum
in the control group (Figure 1A3), and decreased the vascular and
inflammatory components.
To clarify whether these modifications were due to a direct
trastuzumab effect on the peritoneum or a biological effect of
trastuzumab on OVCAR-3 cells, naive nude mice were i.p. injected
once a day, for 3 days with 1ml of either RPMI-1640 (Figure 1A3) or
a 24h serum-free cleared supernatant collected from OVCAR-3WT
cultured cells (Figure 1A4). We observed that the i.p. injection of the
cleared supernatant collected from OVCAR-3WT cultured cells
(Figure 1A4) induced the same inflammatory changes of the
peritoneum (that is, mesothelial hyperplasia, plump and non-
cohesive mesothelial cells and the underlying granulation tissue)
observed in the untreated groups of the peritoneal ovarian carcinoma
(Figure 1A1) and not observed in the control group (RPMI-1640-
injected mice), thus showing that trastuzumab action is related to a
cellular effect on OVCAR-3 cells and not on the mice peritoneum.
Effects of trastuzumab on peritoneal permeability Peritoneal
permeability was assessed according to the 99
mTc-DTPA kinetics
of elimination from the peritoneal cavity (P) and its appearance in
the bladder (Figure 1B and C). Elimination of 99
mTc-DTPA from
the peritoneal cavity increased in mice treated with trastuzumab
compared with untreated mice, the control group of the Figure 1B
and named untreated control-ascites. Higher concentrations of
99
mTc-DTPA appeared in the bladders (B) of treated animals
compared with control mice (Po0.05; Student’s t-test). These data
are the consequence of peritoneal dialysis restoration in treated
animals in relation to the restoration of the peritoneum structure
we have described previously. Results are expressed as mean±
s.e.m. of at least two independent experiments with three mice
per group.
In vitro
In vitro experiments were performed with OVCAR-3WT at an early
passage, OVCAR-3WT cultured 6 months, OVCAR-3A at a early
passage and OVCAR-3A cultured 6 months, because we sought to
not only address the contribution of artefacts due to long-term
culture to our observation but also to justify that the observed
effects are caused by long-time treatment with trastuzumab and
not due to the cumulative acquired mutations that could be
induced by a long-term culture. Our in vitro data did not show any
significant difference between OVCAR-3WT, OVCAR-3A and the
culture passage (data not shown), leading us to present only the
result observed with the 6-month cultured OVCAR-3WT, OVCAR-
3A to be homogenous with the long-time exposure to trastuzumab
cell line, the OVCAR-3LTE subclone.
Cell line proliferation and effects of trastuzumab Regardless of
the heat-decomplemented serum concentration (10 or 2.5%),
OVCAR-3LTE cells proliferated more quickly than did the two
other cell lines, which have similar growth characteristics. At 2.5%
heat-decomplemented serum, OVCAR-3WT, A and LTE cell lines
have a lag time of 24h and a doubling time of 46, 45 and 27.5h,
respectively (Figure 2A).
When the three OVCAR-3 cell line models were maintained in
RPMI-1640 medium containing 10% heat-decomplemented serum,
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strastuzumab had no notable anti-proliferative effect (data not
shown). However, when OVCAR-3WT and A (data not shown for
OVCAR-3A because growth profiles were identical to those of
OVCAR-3WT) cells were cultured in a lower heat-decomplemented
serum concentration (2.5%) and in phenol red-free RPMI-1640
medium, trastuzumab moderately inhibited cell proliferation
in a dose-dependent manner. This inhibition is statistically
significant when comparing untreated cells with trastuzumab-
treated cells at 75, 150 or 300mgml
 1 as previously reported
(Delord et al, 2005) (Figure 2B). In contrast, OVCAR-3LTE cells
were not affected.
Effect of trastuzumab on cellular functions We initially compared
OVCAR-3WT, A and LTE cell lines for plating efficiency and
anchorage-independent growth assays and then for focus forma-
tion and migration capacity. For plating efficiency (Figure 3A3)
and anchorage-independent growth assays (Figure 3A2), using the
soft agar culture test, OVCAR-3A or LTE cells developed clones
after plating under drastic conditions (300 cells in 60-mm dishes)
and clones in soft agar regardless of the cultured conditions (such
as a medium with or without EGF and insulin at 20ngml
 1 and
10mgml
 1 for OVCAR-3WT or A, respectively), OVCAR-3WT cell
lines did not have these potentialities (Figure 3A2 and A3).
For focus-formation assay, regardless of culture conditions
(medium with or without EGF and insulin for OVACR-3WT
and A), OVCAR-3LTE cells grew only in a monolayer, whereas
OVCAR-3A and WT cells grew at a higher density and formed
numerous foci (Figure 3A1).
Ovarian cancer cells are described in the literature for having a
strong metastatic potential. Therefore, we assessed the migration
properties and showed that only OVCAR-3LTE cells were unable to
settle on created ‘scratch’ wounds, demonstrating that chronic
trastuzumab treatment induced the inhibition of cell-migration
properties (Figure 3B).
Effect of trastuzumab on actin cytoskeleton organisation of
OVCAR-3WT, A and LTE cells Cellular motility capacity implies
a dynamic regulation of the actin cytoskeleton and particularly
those of the cortical network. Thus, we determined whether long-
time exposure to trastuzumab could induce any actin network
remodelling by actin immunostaining using phalloidin toxin
coupled with rhodamine fluorochrome.
The actin cytoskeleton in OVCAR-3WT and A is similar and
different from cytoskeleton in OVCAR-3LTE. As shown in Figure 4,
and regardless of culture conditions (medium with or without
heat-decomplemented serum), OVCAR-3WT and A cells display
10 m
0
5
10
15
20
25
30
35
40
120 360 600 840 1080 1320 1560 1800
Untreated (control-ascites)
TZ-72 h
TZ-48 h
TZ-24 h
Time (s)
9
9
m
T
c
D
T
P
A
 
a
p
p
e
a
r
e
n
c
e
 
i
n
 
t
h
e
 
R
O
I
 
o
f
t
h
e
 
b
l
a
d
d
e
r
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
)
* * * *
*
P Untreated
(control-ascites)
B Control-Ascites-1
B TZ-24 h-1
P TZ-24 h-1 P TZ-48 h-1
B TZ-48 h-1
B TZ-72 h-1
P TZ-72 h-1
Figure 1 (A) Pathological pattern of the peritoneum 20 days after OVCAR-3WT implantation. Nude mice bearing OVCAR-3 macroscopic ascites were
treated with vehicle (A1) or trastuzumab at a dose of 150mgml per day (A2) administered by i.p. route for 72h. Naive nude mice were i.p. injected once a
day for 3 days with 1ml of either RPMI-1640 (A3 control group) or the 24h serum-free cleared supernatant collected from OVCAR-3 cells in culture (A4).
Mice were killed and the peritonea were collected and formalin fixed. Microscopic examination was performed and pictures were taken.
(B) Concentrations of 99
mTc-DTPA over time in the bladder: peritoneal permeability. 99
mTc-DTPA appeared in the bladder more intensively in
treated animals compared with the untreated group. Arbitrary units express the 99
mTc-DTPA intensity detection in the region of interest (ROI) of the
bladder (shortened by ‘B’ and by ‘P’ for the peritoneum:). *Po0.05. Student’s t-test compared untreated group (control-ascites) with trastuzumab (TZ)
treatment groups.
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sonly a cortical actin network, which is not observed in OVCAR-
3LTE cells. By contrast, only OVCAR-3LTE cells present a
well-organised actin cytoskeleton network at 10% heat-decom-
plemented serum or under serum-starved conditions.
Effect of trastuzumab on HER-1 and 2 receptors and downstream
target Under serum-starved conditions, no significant differ-
ences were observed in total and phosphorylated levels of HER-1
expression between the three cell lines (Figure 5A and EIA kit data
LTE
A
WT
T0 12 h
LTE
A
WT
12 3
Figure 2 During the focus-formation assay, OVCAR-3A and WT cells grew at a high density and formed numerous foci (A1). Anchorage-independent
growth assays showing the development of clones in OVCAR-3A and LTE cells (A2). Plating efficiency. (A3) Migration assay, when ‘scratch’ wounds were
created by scraping with a sterile pipette tip to make a gap. Only OVCAR-3LTE cells were not capable of settling the created ‘scratch’ wounds (B).
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snot shown). Moreover, long-term trastuzumab exposure has no
effect on total (Figure 5A) or basal phosphorylation (Figure 5A)
levels of HER-2 between the three cell lines.
When treated with trastuzumab for 72h, we observed that
OVCAR-3WT and A cells showed a significant inhibition of
both phosphorylated and total HER-2 levels under basal (0% heat-
decomplemented serum) and EGF-induced conditions (Figure 5B),
showing that trastuzumab binds to the extracellular domain of
HER-2 and inhibits EGF ligand-induced phosphorylation. How-
ever, in OVCAR-3LTE cells, these effects were not or very weak
if observed.
Molecular mechanisms involved in trastuzumab action Under
serum-starved conditions, trastuzumab treatment (from 24 to
96h) inhibited MAPK and AKT EGF-induced phosphorylation
of OVCAR-3WT and A cell lines (Figure 6A). Under the same
conditions, MAPK and AKT phosphorylations were not, or very
slight when observed, affected in OVCAR-3LTE cells.
Effect of trastuzumab on PTEN pathway and p27
kip Using
western blot analysis, the status of PTEN and p27
kip expression
was assessed in the three cell lines. As shown in Figure 6B, the
active form of the PTEN protein and total p27
kip were strongly
inhibited in OVCAR-3LTE cells compared with the two other cell
lines, whereas the phosphorylated form of MEK1/2 was upregu-
lated in OVCAR-3LTE cells compared with the two other cell lines
(Figure 6B).
Effect of the trastuzumab on RhoB The loss of the migratory
capacity and the modification of the actin cytoskeleton distri-
bution/structure/organisation of the OVCAR-3LTE cell could be
associated with the modification of RhoB expression. Using
western blot, we evaluated RhoB expression in the three cell lines
(Figure 5B) and showed that OVCAR-3LTE cells have a higher
RhoB protein expression level than do OVCAR-3WT and OVCAR-
3A cells. Moreover, trastuzumab treatment (150mg for 72h)
induced upregulation of RhoB in all cell lines (data not shown) and
was associated with the migratory inhibition observed in OVCAR-
3LTE cells. Furthermore, these data highlight a striking inverse
correlation between RhoB expression and PTEN phosphorylation
or p27 expression.
RhoB implication in trastuzumab effects To decipher the RhoB
implication in trastuzumab effects, we chose to study its expres-
sion regulation in control cells (OVACR-3A and WT) by its
upexpression (Adeno-RhoB) and in the long-time exposed derived
cells its inhibition (OVCAR-3LTE, shRNA RhoB). As the observed
regulation and the collected results were fully similar between
OVCAR-3A and WT in the studied properties, we chose to show in
the figures only those of the OVCAR-3A cell line we have used to
generate the cell model long-term trastuzumab-exposed cells
(OVCAR-3LTE). We also studied their actin cytoskeleton organi-
sation, migration capacities and their regulation of PTEN and
0% SVFd 10% SVFd
LTE
A
WT
Figure 3 Actin network. OVCAR-3LTE cells display a dense and well-
organised actin cytoskeleton network at 10% heat-decomplemented serum
or under serum-starvation conditions (A and B, respectively).
HER1-Tot
HER2-Tot
LTE A WT
HER1-P
HER2-P
Tubulin
TZ+EGF
Tot
Tot
P
P
HER-2 A
WT
LTE
Cont TZ EGF
72 h
P
Tot
Tubulin
A
B
Figure 4 Total and phosphorylated levels of HER-1 and HER-2
expression in serum-starvation condition: no significant differences
between cell lines (A). After 72h trastuzumab treatment, phosphorylated
and total HER-2 levels were significantly inhibited under basal (0% heat-
decomplemented serum) and EGF-induced conditions in OVCAR-3WT
and A cells (B).
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sMEK1-2 activity. We showed that RhoB induction (Figure 6A
and B, þ88.9% significant induction: Po0.001 – Student’s t-tests)
in OVCAR-3A (open bars) mimic the actin cytoskeleton network
organisation and density (Figure 6C), inhibit their migration
capacities (Figure 6D) and PTEN and MEK1/2 phosphorylation
regulation observed in OVCAR-3LTE (Figure 5B). On the contrary,
the inhibition (Figure 6A and B,  53.11% significant inhibition:
Po0.001 – Student’s t-tests) of RhoB in OVCAR-3LTE (grey
bars) drive us to observe the OVCAR-3A properties in actin
cytoskeleton organisation and density (Figure 6C), migration
capacities (Figure 6D) and their regulation of PTEN and MEK1-2
(Figure 6A) activity we previously described (Figure 5B).
DISCUSSION
Trastuzumab binds specifically to the extracellular domain of
HER-2 and can induce downregulation and inactivation of the
receptor through several mechanisms, including inhibition of the
cell cycle and the survival pathways. Inactivation, in turn, results in
poorly understood anti-tumoural responses, although trastuzumab
prolongs survival in breast cancer patients when administered in
association with chemotherapy. Furthermore, many patients have
primary resistance to trastuzumab for unknown reasons (Nagata
et al, 2004). However, Nagata et al (2004) have provided data that
clarify the anti-tumoural mechanism of trastuzumab and the
mechanism underlying resistance. They showed that, on binding to
the HER-2 receptor, trastuzumab stabilises and activates the PTEN
tumour suppressor and consequently downregulates the PI3K-
AKT signalling pathway. We have also previously reported that
trastuzumab can cure mice in a model of ovarian carcinoma when
administered in the early stage of relapse (Delord et al, 2005).
These in vivo and in vitro trastuzumab effects were associated with
a slight inhibition of the proliferative signal transduction pathway
(MAPK) and a stronger inhibition of the PI3K/AKT pathway
(Delord et al, 2005).
In this study, we have shown that trastuzumab can restore the
peritoneal structure and normal permeability previously affected
by cancer cells. Trastuzumab modifies peritoneal clearance and the
cancer-peritoneal cross-talk in animals with macroscopic carcino-
matosis. Trastuzumab was shown to modify cancer cell functions
and biology through the regulation of several molecular targets,
such as PTEN, MEK1-2 and RhoB. These results suggest that the
anti-invasive function of trastuzumab leading to cure mice in a
micrometastasis model of ovarian cancer involves a possible cross-
talk between RhoB and the PTEN pathway.
All normal serous membranes, such as the peritoneum, consist
of a single layer of flat mesothelial cells resting on a basement
membrane, with a submesothelial layer of connective tissue
involved in fluid transport. In the murine model of ovarian
carcinoma, substantial alterations to the peritoneum were
observed both at the macroscopic and submacroscopic levels.
Such alterations may include thickening of the surface membrane
with malignant ascites formation and infiltration. At the micro-
scopic level, there may be multilayering of the surface epithelium
(hyperplasia) and an inflammatory infiltrate composed of different
leukocyte populations. The administration of serum-free super-
natant collected from OVCAR-3WT-cultured cells induced the
same inflammatory and structural changes of the peritoneum as
carcinomatosis. Trastuzumab reversed these modifications and
72 h 72 h 72 h 72 h
LTE A WT
RhoB
p27Kip
MEK1/2-P
PTEN-P
PTEN-Tot
Tubulin
MEK1/2-Tot
TZ+EGF TZ EGF
Tot
P
Tot
P
Tot
P
LTE
Tot
P
Tot
P
Tot
P
Cont Cont TZ EGF TZ+EGF
WT
A MAPK
Tubulin Tubulin
Tubulin
Tubulin
AKT
Figure 5 Total and phosphorylated protein levels. Trastuzumab treatment (from 24 to 96h) inhibited MAPK and AKT EGF-induced-phosphorylation of
OVCAR-3WT and A cell lines under serum-starvation conditions. (A) Western blot analysis showing in OVCAR-3LTE cells: inhibition of the active form
of PTEN and total p27
kip, upregulation of phosphorylated MEK1/2, and higher RhoB protein level expression (B).
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sinduced the restoration of peritoneal dialysis. These results suggest
that effect of trastuzumab on ovarian carcinoma cells may result
from inhibition of one or more secreted molecules or pathways
involved in the processes of anchorage, proliferation and
migration of ovarian carcinoma. The identification of these
molecules and pathways is currently under investigation.
We have previously shown that proliferation of OVCAR-3LTE
cells is higher compared with control cell lines (Delord et al, 2005),
suggesting once again that the inhibition of the cellular prolifera-
tion induced by trastuzumab does not fully explain its mechanism
of action. The inhibition of proliferation is certainly a significant
mode of action of trastuzumab in cellular models overexpressing
the HER-2 receptor (Longva et al, 2005), but OVCAR-3 cells and
the derived subclones used in this study do not amplify or
overexpress HER-2. Our results suggest that trastuzumab is also
effective in models that do not overexpress HER-2 when used in
minimal disease, during the early stages of repopulation and
invasion.
To determine whether trastuzumab induces modifications of
cellular functions, comparisons were first made between OVCAR-
3WT, A and LTE cell lines in terms of plating efficiency and
anchorage-independent growth assays. Only OVCAR-3A and LTE
cells were able to develop clones after plating under drastic
conditions and in soft agar. This indicates that OVCAR-3WT
in vivo passage contributed to select clones with these cellular
properties, which cannot be correlated with trastuzumab long-time
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Figure 6 (A) Western blot analysis showing that inhibition of RhoB (shRNA-RhoB) in OVCAR-3LTE reverses the downregulation of phospho-PTEN and
the upregulation of phospho-MEK1/2. Induction of RhoB (adeno-RhoB) in OVCAR-3A mimics the PTEN and MEK1/2 phosphorylation regulation observed
in OVCAR-3LTE (panel A). (B) Histogram represents the quantisation of the statistically significant RhoB induction (adeno-RhoB, þ88.9%) in OVCAR-3A
and RhoB statistically significant downregulation (shRNA-RhoB,  53.11%) (panel B) observed by western blot (panel A). (C) Actin
network. Inhibition of RhoB (shRNA-RhoB) in OVCAR-3LTE reverses actin cytoskeleton network organisation and density as observed in control
cell lines (OVCAR-3A). Induction of RhoB (Adeno-RhoB) in OVCAR-3A cells mimics the actin cytoskeleton network organisation and density
observed in OVCAR-3LTE cells (panel C). (D) Migration assay, when ‘scratch’ wounds were created by scraping to make an gap, RhoB inhibition
(shRNA-RhoB) in OVCAR-3LTE restores migration capacities observed in control cell lines; on the contrary, induction of RhoB (Adeno-RhoB) in control
cell lines (OVCAR-3A and OVCAR-3WT-data not shown) inhibits their migration as observed in long-time trastuzumab-exposed cell line OVCAR-3LTE
(panel D).
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sexposure, but only to in vivo passage. Loss-of-contact inhibition
properties constitute an important characteristic of transformed
cells. This was assessed by focus-formation assays and migration
capacity. Restoration of cellular contact inhibition and inhibition
of cellular migration capacity was observed in OVCAR-3LTE.
These results strongly suggest that the trastuzumab effect could
modify two major functions of transformed cells: contact
inhibition and invasion.
On the basis of these results, we hypothesised that in mice,
trastuzumab treatment could inhibit the early stages of tumour
growth, migration and invasion, which probably are key processes
of early tumour re-growth. The cellular migration phenomenon
relies on a complex protein network of actin filaments, which
extend across the cytoplasm associated with a cortical network
and participates in the regulation of the filopodia, lamellipodia
or ruffles formation (Hall, 2005). This network is a dynamic
multiproteic structure, which reorganises the cell morphology
continuously during cell division or in response to different
stimuli (Gov and Gopinathan, 2006).
Members of the Rho GTPase family are mediators of diverse
cellular functions, such as the regulation of actin cytoskeleton
organisation or migration (Hall, 2005). Although Cdc42 promotes
filopodia formation, Rac1 promotes formation of lamellipodia and
membrane ruffles, RhoA triggers actin stress fibre and focal
adhesion formation (Kozma et al, 1995; Nobes et al, 1998).
Consequently, Rho GTPase functions can influence cell–cell and
cell–substratum interactions, which in turn can modulate cell
movement. From actin network studies, we showed that trastuzu-
mab chronic treatment of OVCAR-3LTE cells induced the
formation of a cytoplasmic actin stress fibre network. As described
by Nobes et al (1998), the cortical network is linked to the function
of Rac and Cdc42 proteins (Kozma et al, 1995) and is also
associated with cellular migration, motility and invasion (Keely
et al, 1997). These data are in agreement with our results showing a
correlation between the absence of this cortical network and the
inhibition of the migratory capacity observed in the OVCAR-3LTE
cell line.
It is well known that the GTPases of the Rho family such as
RhoA, RhoB and RhoC are implicated in the control of actin
cytoskeleton rearrangement and thus in cellular migration (Van
Aelst and D’Souza-Schorey, 1997; Hall, 2005). We show in this
study that RhoB induction in control cell lines (OVCAR-3A and
WT) and its inhibition in OVCAR-3LTE is critical in ovarian cell
lines we used for migration capacities and certainly for tumour
aggressiveness together induced by trastuzumab treatment.
Mazie `res et al (2004) demonstrated in a study on human lung
cancer tissues, a correlation between RhoB loss of expression and a
worse tumour stage. These data suggest that RhoB is implicated in
the regulation of malignant transformation and progression.
Moreover, Jiang et al (2004) identified suppression of RhoB as a
mechanism inducing tumour metastasis. In our cell lines,
trastuzumab treatment induced an increase in RhoB protein levels,
which is associated with the inhibition of cellular migration. To
validate the link between trastuzumab, RhoB and these properties
controlled by actin cytoskeleton and cortical network organisation
and regulation, we performed a series of experiments of RhoB
expression variation. We have shown that inhibition of these
properties are concomitant to the upregulation of RhoB in control
cells lines (OVCAR-3WT and A) and their restorations are
associated with RhoB inhibition in the long time exposed to the
trastuzumab cell line (OVCAR-3LTE). The data presented in this
study together with the available literature demonstrate that
trastuzumab action in the repopulation stage involves cytoskeleton
modulation and migration properties by the regulation of the Rho
GTPase family and more specifically RhoB.
Elsewhere, we have also assessed whether trastuzumab treat-
ment could induce a positive regulation of HER-1, which could be
involved in trastuzumab resistance after long exposure (Delord
et al, 2005). The level of phosphorylated and total HER-1 was
measured in the three cell lines and there was no observed
difference. Moreover, in OVCAR-3LTE cells, we observed the
loss of HER-2 and downstream pathway regulation, indicating
that the receptor and pathway of these cells were modified in
response to the drug. The long-time exposure to trastuzumab
could render the HER-2 receptor of this cell line capable of
bypassing trastuzumab inhibition. However, this mechanism has
not been fully investigated in this study as it was a not primary
objective.
In breast cancer models, many in vitro studies have indicated a
link between the effects of trastuzumab and PTEN (Nahta et al,
2004; Pandolfi, 2004) and p27
kip. In this study, we showed in
OVCAR-3LTE the loss of the phosphorylated form of PTEN
(deleted from chromosome 10) and a strong inhibition of the total
form of p27
kip associated with the upregulation of the phosphory-
lated form of the protein MEK1/2 and RhoB upregulation.
Moreover, these observed regulations highlight an inverse
correlation between RhoB expression and PTEN and p27 down-
regulation, strongly suggesting the RhoB implication in the
trastuzumab action and certainly resistance.
Nagata et al (2004) reported that the loss of PTEN expression in
breast cancer cell lines overexpressing HER-2 confers resistance to
trastuzumab. The data from the present ovarian cell line studies
show that response to trastuzumab involves the regulation of
PTEN and p27
kip expression. The inhibition of PTEN activity
observed in this study could be partly responsible for the
insensitivity to trastuzumab in terms of the proliferation observed
in OVCAR-3LTE cells. Indeed, PTEN is a tumour suppressor
involved in the regulation of many cellular process, such as
regulation of the cell cycle (G1/S), apoptosis, the rearrangement of
the cytoskeleton and migration (Wu et al, 2003; Raftopoulou et al,
2004). Moreover, PTEN is reported to have at least two main
molecular functions: (Wu et al, 2003) protein phosphatase and
lipid phosphatase activity.
The protein phosphatase activity is involved in the inhibition
of growth factor-stimulated MAPK signalling. The loss of PTEN
protein phosphatase activity induces the expression of the
phosphorylated form of MEK1/2 as observed herein in OVCAR-
3LTE cells. The protein phosphatase activity is also involved in the
reorganisation of the actin cytoskeleton (Attwell et al, 2003), the
regulation of migration (Raftopoulou et al, 2004) and the cellular
invasion process (Sanchez et al, 2005) by inhibition of focal
adhesion kinase. Indeed, PTEN, by its protein phosphatase activity
is responsible for the inhibition of cellular migration. In our
model, PTEN phosphatase activity is possibly preserved despite a
strong decrease in its phosphorylated form. Consequently,
migration properties are not affected in the cell line long-time
exposed to trastuzumab. As discussed, RhoB is probably involved
in the changes observed in migration. Furthermore, and for the fist
time for trastuzumab molecular effects, we showed a direct link
between PTEN activity and RhoB expression both related to
trastuzumab action. We have shown that inhibition of PTEN
phosphorylation level is concomitant to the upregulation of RhoB
expression in control cells lines (OVCAR-3WT and A), and on the
contrary, RhoB inhibition in the long-time exposed to trastuzumab
cell line (OVCAR-3LTE) is associated to PTEN phosphorylation
increase. This PTEN regulation process, we imply to trastuzumab
under the RhoB control, is corroborated by the MEK1/2
phosphorylation level modification that we describe in the
experiments of induction/inhibition of RhoB expression we
performed. Indeed, a cross-talk effect between RhoB and PTEN
could strongly be evoked in the cellular effect of trastuzumab.
RhoB expression modulation could be similar to PTEN regulation
(Nagata et al, 2004), a marker of the biological and molecular effect
of trastuzumab in our model.
The second function of PTEN is the inhibition of AKT by lipid
phosphatase activity, which has a major role in anti-proliferative
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sand pro-apoptotic mechanisms. Indeed, the PTEN lipid phospha-
tase activity contributes to the regulation of the cellular cycle by
p27
kip induction. Trastuzumab resulted in p27
kip protein levels in
OVCAR-3LTE cells. p27
kip is a cyclin-dependent kinase inhibitor
involved in the inhibition of cell-cycle progression in the G1/S
phase. The p27
kip inhibition seen in OVCAR-3LTE cells could be
involved in the stimulation of proliferation that was observed.
Nevertheless, the increase in proliferative capacities has no affect
on the invasive properties in our model.
The data presented in this study suggest that trastuzumab
properties are complex, but also highlight a significant effect
of this agent in the early stages of tumour invasion as a
consequence of PTEN and RhoB regulation. Further experi-
ments will be developed with complementary ovarian carcinoma
cell lines overexpressing HER-2 receptor to decipher the role
of RhoB/PTEN cross-talk and/or expression vs the HER-2
expression level to increase our knowledge in ovarian carcinomas
treatment.
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